Roles of Substance P and NK1 Receptor in the Brainstem in the Development of Emesis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated. -
Antiemetics/Antivertigo Agents
Antiemetic Agents Therapeutic Class Review (TCR) May 1, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. May 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2019 Magellan Rx Management. All Rights Reserved. 3 FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) NK1 receptor antagonists aprepitant capsules generic, Merck In combination with other antiemetic agents for: (Emend®)1 . -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
HHS Template for Reports, with Instructions
Texas Vendor Drug Program 1.1 Drug Use Criteria: Substance P/Neurokinin1 Receptor Antagonists Publication History 1. Developed December 2003. 2. Revised September 2020; September 2018; September 2016; May 2015; August 2013; June 2013; September 2011; October 2009; February 2006; January 2006. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: • Drug Information Service, UT Health San Antonio. • The College of Pharmacy, The University of Texas at Austin. 1 1 Dosage [*] Current therapies for chemotherapy-induced nausea/vomiting (CINV) and post- operative nausea and vomiting (PONV) target corticosteroid, dopamine, and serotonin (5-HT3) receptors. In the central nervous system, tachykinins and neurokinins play a role in some autonomic reflexes and behaviors. Aprepitant is a selective human substance P/neurokinin 1 (NK1) antagonist with a high affinity for NK1 receptors and little, if any, attraction for corticosteroid, dopamine, or 5-HT3 receptors. Rolapitant (Varubi®), the newest substance P/NK1 antagonist, is FDA- approved to prevent delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults. Combination therapy including netupitant, a substance P/NK1 antagonist and palonosetron, a selective 5-HT3 receptor antagonist (Akynzeo®), is now available to prevent acute and delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults. -
The Significance of NK1 Receptor Ligands and Their Application In
pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59). -
(12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII. -
Ep 2522664 B1
(19) TZZ _T (11) EP 2 522 664 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 401/04 (2006.01) C07D 413/04 (2006.01) 12.04.2017 Bulletin 2017/15 A61K 31/4545 (2006.01) (21) Application number: 12169655.3 (22) Date of filing: 29.06.2005 (54) Piperidine derivatives as NK1 antagonists Piperidinderivate als NK1-Antagonisten Dérivés de pipéridine en tant qu’ antagonistes NK1 (84) Designated Contracting States: • Wrobleski, Michelle Laci AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Whitehouse Station, NJ New Jersey 08889 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR • Rao, Ashwin U. Designated Extension States: Avenel, NJ New Jersey 07001 (US) AL BA HR LV MK YU • Wang, Cheng King of Prussia, PA Pennsylvania 19406 (US) (30) Priority: 01.07.2004 US 584502 P • Shah, Sapna S. Westampton, NJ New Jersey 08060 (US) (43) Date of publication of application: 14.11.2012 Bulletin 2012/46 (74) Representative: Simpson, Tobias Rutger Mathys & Squire LLP (62) Document number(s) of the earlier application(s) in The Shard accordance with Art. 76 EPC: 32 London Bridge Street 05787862.1 / 1 799 666 London SE1 9SG (GB) (73) Proprietor: OPKO Health, Inc. (56) References cited: Miami, FL 33137 (US) WO-A-03/042173 WO-A-03/051840 (72) Inventors: • WU X ET AL: "Stereoselective Transformation of • Palani, Anandan 2H-1,4-Oxazin-2-ones into 2,(2),5,5-Tri- and Bridgewater, NJ New Jersey 08807 (US) Tetrasubstituted Analogues of • Shih, Neng-Yang cis-5-Hydroxy-2-piperidinemethanol and Warren, NJ New Jersey 07059 (US) cis-5-Hydroxy-6-oxo-2-piperidi necarboxylic • Huang, Xianhai Acid", TETRAHEDRON, ELSEVIER SCIENCE Warren, NJ New Jersey 07059 (US) PUBLISHERS, AMSTERDAM, NL, vol. -
Quantitative Analysis of NK1 Receptor in the Human Brain Using PET with 18F-FE-SPA-RQ
Quantitative Analysis of NK1 Receptor in the Human Brain Using PET with 18F-FE-SPA-RQ Masaki Okumura1,2, Ryosuke Arakawa1,2, Hiroshi Ito1, Chie Seki1, Hidehiko Takahashi1, Harumasa Takano1, Eisuke Haneda1,3, Ryuji Nakao4, Hidenori Suzuki3, Kazutoshi Suzuki4, Yoshiro Okubo2, and Tetsuya Suhara1 1Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan; 2Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan; 3Department of Pharmacology, Nippon Medical School, Tokyo, Japan; and 4Molecular Probe Group, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan tachykinins—substance P (SP), neurokinin A, and neuro- 18F-fluoroethyl-SPA-RQ (18F-FE-SPA-RQ) was recently devel- kinin B—are known, and they share a consensus amino oped as a radioligand for the measurement of neurokinin 1 (NK1)re- acid sequence (-Phe-X-Gly-Leu-Met-NH ) in their car- 18 2 ceptor with PET. In this study, we used F-FE-SPA-RQ with PET to boxyl terminals (1–4). SP is a well-characterized neuro- visualize and quantify NK1 receptor in the human brain. Methods: PET scans were performed on 7 healthy men after intravenous injec- peptide, participating in neurotransmission by itself or 18 tion of F-FE-SPA-RQ. Binding potential (BPND) was calculated by synergistically with other neurotransmitters such as mono- theindirectkinetic,simplifiedreferencetissuemodel(SRTM),andra- amines, acetylcholine, and glutamate in nerve terminals. tio methods. The indirect kinetic method was used as the gold stan- Receptors for tachykinins—termed neurokinin 1 (NK1), dard method and was compared with the SRTM method, with scan NK , and NK receptors—have been identified (all are G times of 180, 270, and 330 min, and with the ratio method, with time 2 3 integration intervals of 120–180, 210–270, and 300–330 min. -
Emerging Targets for Antidepressant Therapies Jeffrey J Rakofsky1, Paul E Holtzheimer2 and Charles B Nemeroff2
Available online at www.sciencedirect.com Emerging targets for antidepressant therapies Jeffrey J Rakofsky1, Paul E Holtzheimer2 and Charles B Nemeroff2 Despite adequate antidepressant monotherapy, the majority of 70% of depressed patients have residual symptoms [3], depressed patients do not achieve remission. Even optimal and and, even with more aggressive therapies, 20% or more aggressive therapy leads to a substantial number of patients may show only a limited response [4]. Rather than being who show minimal and often only transient improvement. In the exception, recurrent episodes are the rule, and there order to address this substantial problem of treatment-resistant are few evidence-based approaches to help clinicians depression, a number of novel targets for antidepressant maintain a patient’s antidepressant response. Persistent therapy have emerged as a consequence of major advances in depression is associated with an increase in substance and the neurobiology of depression. Three major approaches to alcohol abuse, an increased risk for suicide and for car- uncover novel therapeutic interventions are: first, optimizing the diovascular disease. Thus, improved treatments for modulation of monoaminergic neurotransmission; second, depression are urgently needed. developing medications that act upon neurotransmitter systems other than monoaminergic circuits; and third, using Various forms of psychotherapy, pharmacotherapy, and focal brain stimulation to directly modulate neuronal activity. electroconvulsive therapy (ECT) are currently the most We review the most recent data on novel therapeutic commonly used antidepressant treatments. Serendipitous compounds and their antidepressant potential. These include discoveries and/or a limited understanding of the triple monoamine reuptake inhibitors, atypical antipsychotic neurobiology of depression which largely focused on the augmentation, and dopamine receptor agonists. -
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0 -
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
Download of These Slides, Please Direct Your Browser to the Following Web Address
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology October 2015 Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials Discussants Eric Roeland, MD Director of Clinical Research in Symptom Intervention Assistant Clinical Professor of Medicine University of California, San Diego Moores Cancer Center La Jolla, California Matti S. Aapro, MD Dean of the Multidisciplinary Oncology Institute A CME Activity Clinique de Genolier Approved for Genolier, Switzerland 1.25 AMA PRA Category 1 Credit(s) TM Lee S. Schwartzberg, MD Professor of Medicine Chief, Division of Hematology & Oncology Release Date: October 2015 The University of Tennessee Health Science Center Expiration Date: October 31, 2016 Memphis, Tennessee Estimated time to complete activity: 1.25 hours Project ID: 11026 Abstract: Chemotherapy-induced nausea and vomiting (CINV) is among the most feared and debilitating adverse events experienced by cancer patients. Left unaddressed, CINV symptoms not only decrease quality of life, but may also affect patients’ willingness to continue chemotherapy treatment. Detailed guidelines are available that outline best practices for prophylaxis of acute and delayed CINV. However, adherence to guideline recommendations continues to be suboptimal, and many patients still suffer unnecessarily from CINV. In addition, breakthrough/refractory CINV continues to present particular challenges. The development of effective CINV treatments with diverse mechanisms of action has expanded the options available for preventing symptoms. The US Food and Drug Administration has recently approved several new therapies for the management of CINV. NEPA is a fixed-dose combination of netupitant (300 mg) plus palonosetron (0.5 mg). In combination with dexamethasone, NEPA has demonstrated superior efficacy to palonosetron alone in patients receiving highly or moderately emetogenic chemotherapy.